110 related articles for article (PubMed ID: 832410)
1. Simple gas chromatographic analysis of plasma dopa and dopamine.
Mizuno Y
Clin Chim Acta; 1977 Jan; 74(1):11-9. PubMed ID: 832410
[TBL] [Abstract][Full Text] [Related]
2. Improved high-performance liquid chromatographic analysis with double detection system for L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients under L-dopa therapy.
Betto P; Ricciarello G; Giambenedetti M; Lucarelli C; Ruggeri S; Stocchi F
J Chromatogr; 1988 Dec; 459():341-9. PubMed ID: 3243910
[TBL] [Abstract][Full Text] [Related]
3. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Mizuno Y; Yoshida M; Obayashi T; Ueki A
Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
[No Abstract] [Full Text] [Related]
4. Accumulation of dopamine by blood platelets from normal subjects and parkinsonian patients under treatment with L-DOPA.
Boullin DJ; O'Brien RA
Br J Pharmacol; 1970 Aug; 39(4):779-88. PubMed ID: 5485151
[TBL] [Abstract][Full Text] [Related]
5. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
[No Abstract] [Full Text] [Related]
6. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
Granerus AK; Jagenburg R; Rödjer S; Svanborg A
Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
[No Abstract] [Full Text] [Related]
7. 3,4-dihydroxyphenylalanine (DOPA) decarboxylase deficiency and resultant high levels of plasma DOPA and dopamine in unfavorable neuroblastoma.
Ikeda H; Matsuyama S; Suzuki N; Takahashi A; Kuroiwa M
Hypertens Res; 1995 Jun; 18 Suppl 1():S209-10. PubMed ID: 8529065
[TBL] [Abstract][Full Text] [Related]
8. Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor.
Dutton J; Copeland LG; Playfer JR; Roberts NB
Clin Chem; 1993 Apr; 39(4):629-34. PubMed ID: 8472357
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous measurement of L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients by improved sample pretreatment and high-performance liquid chromatographic determination.
Lucarelli C; Betto P; Ricciarello G; Giambenedetti M; Corradini C; Stocchi F; Belliardo F
J Chromatogr; 1990 Jul; 511():167-76. PubMed ID: 2211908
[TBL] [Abstract][Full Text] [Related]
10. Determination of 3,4-dihydroxyphenylalanine (DOPA) in plasma and cerebrospinal fluid by high performance liquid chromatography with electrochemical detection.
Boomsma F; van der Hoorn FA; Man in 't Veld AJ; Schalekamp MA
Clin Chim Acta; 1988 Nov; 178(1):59-69. PubMed ID: 3147824
[TBL] [Abstract][Full Text] [Related]
11. A method for the determination of dopa and 3-O-methyldopa in the plasma of Parkinsonian patients.
Curzon G; Kantamaneni BD; Trigwell J
Clin Chim Acta; 1972 Mar; 37():335-41. PubMed ID: 5022098
[No Abstract] [Full Text] [Related]
12. Liquid chromatographic method for monitoring therapeutic concentrations of L-dopa and dopamine in serum.
Riggin RM; Alcorn RL; Kissinger PT
Clin Chem; 1976 Jun; 22(6):782-4. PubMed ID: 1277462
[TBL] [Abstract][Full Text] [Related]
13. Method for the determination of gamma-L-glutamyl-L-dihydroxyphenylalanine and its major metabolites L-dihydroxyphenylalanine, dopamine and 3,4-dihydroxyphenylacetic acid by high-performance liquid chromatography with electrochemical detection.
Cummings J; Matheson LM; Smyth JF
J Chromatogr; 1990 Jun; 528(1):43-53. PubMed ID: 2117019
[TBL] [Abstract][Full Text] [Related]
14. [Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
Perret J; Feuerstein C; Pellat J; Serre F; Gavend M; Tanche M
Rev Neurol (Paris); 1977 Nov; 133(11):627-36. PubMed ID: 601391
[TBL] [Abstract][Full Text] [Related]
15. DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.
Hare TA; Beasley BL; Chambers RA; Boehme DH; Vogel WH
Clin Chim Acta; 1973 May; 45(3):273-80. PubMed ID: 4708057
[No Abstract] [Full Text] [Related]
16. Radioenzymatic assay of DOPA (3,4-dihydroxyphenylalanine).
Johnson GA; Gren JM; Kupiecki R
Clin Chem; 1978 Nov; 24(11):1927-30. PubMed ID: 709823
[TBL] [Abstract][Full Text] [Related]
17. Effect of L-dopa on plasma free fatty acids and plasma glucose.
Rivera-Calimlim L; Bianchine JR
Metabolism; 1972 Jul; 21(7):611-7. PubMed ID: 5040916
[No Abstract] [Full Text] [Related]
18. Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms.
Papavasiliou PS; McDowell FH; Wang YY; Rosal V; Miller ST
Neurology; 1979 Feb; 29(2):194-200. PubMed ID: 571063
[TBL] [Abstract][Full Text] [Related]
19. An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.
Mones RJ
J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):362-7. PubMed ID: 4714098
[TBL] [Abstract][Full Text] [Related]
20. Dihydroxyphenylalanine (DOPA) in plasma during dopa treatment of patients with Parkinson's disease.
Tyce GM; Muenter MD; Owen CA
Mayo Clin Proc; 1970 Jun; 45(6):438-43. PubMed ID: 5425103
[No Abstract] [Full Text] [Related]
[Next] [New Search]
